Immunovant earnings date
Immunovant (4YB) Q2 2027 Earnings Report
DE:4YB Q2 2027 EPS Results
- Actual EPS
- -EUR 0.42
- Consensus EPS
- -EUR 0.66
- Beat/Miss
- Beat by +EUR 0.24
- One Year Ago EPS
- -EUR 0.66
DE:4YB Q2 2027 Revenue Results
- Actual Revenue
- EUR 0
- Expected Revenue
- EUR 0
- Beat/Miss
- Met expectations
- YoY Revenue Growth
- ―
Earnings Announcement Details
- Quarter
- Q2 2027
- Date
- 11/09/2026
- Time
- Before Open
- Conference Call
- Monday, November 9, 2026
Immunovant's next earnings date is estimated for February 16, 2027, based on past reporting schedules.
Q2 2027 Earnings Call Audio
Q2 2027 Earnings Slide Deck
No slide deck is available for this earnings event.
Q2 2027 Earnings Call Summary
The call was strongly positive, driven by the successful LISRAYA launch, robust early commercial demand, positive 1402 RA maintenance data, favorable NIU results, and compelling mosliciguat PH-ILD data. The company also has substantial cash, active share repurchases, and a broad 2027 pipeline. The main negative items were the failed CLE study, the likely discontinuation of Sjögren's development, ongoing uncertainty around the 1402 regulatory path, a potential modest near-term inventory headwind, and the quarterly net loss. Highlights significantly outweighed lowlights.
For LISRAYA, management expects “a modest headwind” from inventory dynamics in the December quarter and expects inventory and stocking to be “completely irrelevant as we round the corner into next year”; for IMVT-1402, it expects to update trial plans “probably later this year or early next year” after FDA discussions. In 2027, Roivant expects to file the sNDA for NIU, report top-line data for 1402 in Graves’ and data in MG, and pursue “multiple program indication expansion,” while for mosliciguat it expects updates “in the coming months” on initiation of other trials, with a “pretty broad program” under consideration across PAH, IPF, PPF, and other forms of pulmonary hypertension, although it cannot commit to specific indications or whether they will be phase IIs or phase IIIs. It also expects to provide an update “relatively soon” on Graves’ timing and enrollment.
- LISRAYA Commercial Launch Shows Strong Initial DemandLISRAYA was approved in August and generated $31 million of net revenue during approximately five weeks on the market through September 30. Hundreds of patients were on paid drug at quarter-end, many hundreds were on paid drug by the call, and the company reported a broad initial prescriber base, strong patient and physician enthusiasm, and good early payer uptake.
- Broad LISRAYA Prescriber and Patient AdoptionMany hundreds of prescribers had written LISRAYA prescriptions. Uptake included patients switching from off-label JAKs, IVIg, steroids, and immunosuppressants, as well as some newly diagnosed patients. The company said the launch was reaching a broad patient population.
- Early LISRAYA Access Has Been Generally StraightforwardThe company reported good conversion rates from prescriptions to paid prescriptions and said early payer coverage had been straightforward, with no significant change in access relative to the early launch period. Some national plans required only a prior systemic immunosuppressant, although other plans imposed more significant restrictions.
- Strong 1402 Rheumatoid Arthritis Maintenance DataIn Period 2 of the randomized-withdrawal RA study, 92.5% of patients who continued on 600 mg maintained an ACR20 response at week 28, compared with approximately 75% on placebo. The 600 mg arm achieved a p-value on the primary endpoint, while 300 mg performed similarly to placebo. The study enrolled a difficult-to-treat, fourth-line-plus population that had failed conventional therapy and at least two advanced treatment mechanisms.
- 1402 Demonstrated Sustained and Deeper ResponsesAt week 28, 80% of patients receiving 600 mg had an ACR50 response versus 56% on placebo, with additional separation on ACR70. ACR50 and ACR70 responses on 600 mg began appearing as early as week 4 and continued improving through the study. The company also reported separation from placebo on CDAI and SDAI, and said the JAK-experienced subset performed about as well as the overall population.
- 1402 Safety Profile Remained FavorableSafety in the Period 2 RA study was described as entirely consistent with prior results, with event rates comparable to placebo, no new safety signals, and the drug continuing to appear safe and well-tolerated.
- High Unmet Need and Commercial Opportunity for 1402 in Refractory RAThe company estimates approximately 85,000 patients in the U.S. with refractory RA relevant to the program. These patients had failed multiple therapies, including TNFs, JAK inhibitors, and in some cases IL-6 therapies. Management said the Period 2 data supported deep therapeutic responses and an important potential role for 1402.
- NIU Data Supported a Potential New Standard of CareIn the CLARITY studies, brepocitinib met the primary and all secondary endpoints in both studies. Median treatment failure was not reached over 48 weeks versus treatment failure in placebo patients at around 12 weeks, and almost two-thirds of patients achieved steroid-free quiescence. The company described the results as statistically and clinically meaningful, consistent across subgroups, and generally well-tolerated.
- Mosliciguat Delivered Strong PH-ILD EfficacyIn PH-ILD, mosliciguat produced a 56% placebo-adjusted PVR reduction at week 16 and a statistically significant 35 m improvement in six-minute walk distance on the key secondary endpoint. Week 24 exploratory analyses showed meaningful NT-proBNP benefits and a strong six-minute walk result, while cardiac and hemodynamic measures were described as phenomenal.
- Mosliciguat Showed Favorable Tolerability and Broad Development PotentialNinety-eight percent of patients achieved the high dose, supporting a positive safety and tolerability signal. Cough rates were lower than placebo despite the tolerability challenges associated with treprostinil. The Phase III PH-ILD study was actively screening and enrolling, and the company said it was evaluating additional indications including PAH, IPF, and PPF, with a broad program under consideration.
- Strong Financial Liquidity and Share RepurchasesCash was $4.2 billion as of September 30, partly reflecting receipts from the Moderna litigation. During the six months ended September 30, the company repurchased approximately $280 million of stock, representing about 9.4 million shares.
- Positive Pipeline Momentum for 2027The company expects to file an sNDA for NIU and pursue another indication for brepocitinib. It also expects top-line data for 1402 in Graves' disease and myasthenia gravis, as well as multiple program and indication expansion activities. Management said enrollment in Graves' disease had been strong and that additional timing details were expected relatively soon.
DE:4YB Earnings History
| Report Date | Fiscal Quarter | Forecast / EPS | Last Year's EPS | EPS YoY Change | Press Release |
|---|---|---|---|---|---|
| Feb 16, 2027 | 2027 (Q3) | -0.53- | -0.55 | ― | ― |
| Nov 09, 2026 | 2027 (Q2) | -0.66-0.42 | -0.66 | 35.62% (+0.23) | |
| Aug 06, 2026 | 2027 (Q1) | -0.57-0.68 | -0.64 | -5.63% (-0.04) | |
| May 20, 2026 | 2026 (Q4) | -0.53-0.66 | -0.58 | -14.06% (-0.08) | |
| Feb 06, 2026 | 2026 (Q3) | -0.64-0.55 | -0.68 | 19.74% (+0.14) | |
| Nov 10, 2025 | 2026 (Q2) | -0.64-0.66 | -0.67 | 1.35% (+0.01) | |
| Aug 11, 2025 | 2026 (Q1) | -0.61-0.64 | -0.54 | -18.33% (-0.10) | |
| May 29, 2025 | 2025 (Q4) | -0.64-0.58 | -0.47 | -23.08% (-0.11) | |
| Feb 06, 2025 | 2025 (Q3) | -0.68-0.68 | -0.26 | -162.98% (-0.42) | |
| Nov 07, 2024 | 2025 (Q2) | -0.54-0.67 | -0.41 | -64.44% (-0.26) |
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
